Regulators ponder response to Concerta complications

Faced by a host of disturbing complications linked to Johnson & Johnson's Concerta, regulators at the FDA are pondering the best way to alert providers. Regulators say that patients taking Concerta -- a once-daily form of Ritalin -- have experienced hallucinations, suicidal thoughts, high blood pressure and psychotic behavior, according to a report in the Los Angeles Times.

"The FDA is pursuing additional means to better characterize the cardiovascular risks for all drug products approved for ADHD," the agency said in its statement. "Potential options under consideration include population-based pharmaco-epidemiologic studies, long-term safety trials and other targeted CV risk studies."

- read this article from the Los Angeles Times

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.